Delphia Therapeutics
0 followers
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that... Read more
Org chart
Kevin Marks
President & CEO
Kevin Marks
Collapse
Aimee Usera
Vp, Head Of Chemistry
Michael Acker
Vice President, Biomolecular Sciences
Bryan Gutierrez
Vice President And Head Of Operations
Michael D.
Co-founder
Jill Parolin
Director, Human Resources
Stella Paffenholz
Board Observer
